Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is poised for significant growth thanks to its innovative Deep TMS technology, which has shown comparable remission and response rates to traditional protocols while significantly reducing the number of clinic visits required. In addition, the recent FDA approval of Neurolief's ProlivRx device for at-home use and the company's strategic investment in Neurolief further enhance its potential. Furthermore, BrainsWay's virtual analyst and investor day demonstrated strong tailwinds for the company, including ongoing transformation of neuropsychiatry and the quantum leap of its Deep TMS360 technology.

Bears say

BrainsWay is an innovative company with a solid financial performance, evidenced by its 2025 top-line revenue totaling $52.2 million and full-year diluted earnings of $0.18 per share. However, we have a negative outlook on the stock due to the recent reduction in the ratio of American Depositary Shares (ADSs) to ordinary shares, the need for continued investments to drive revenue growth, and the limited coverage of its accelerated Deep TMS protocol for the treatment of MDD. Additionally, the stock's performance may be impacted by the company's dependence on lease agreements for customer engagements and the potential for limited reimbursement from insurance providers.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of May 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.